India
· Delayed Price · Currency is INR Neuland Laboratories Statistics
Total Valuation
Neuland Laboratories has a market cap or net worth of INR 178.35 billion. The enterprise value is 177.54 billion.
| Market Cap | 178.35B |
| Enterprise Value | 177.54B |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 7.13M |
Valuation Ratios
The trailing PE ratio is 63.77.
| PE Ratio | 63.77 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 16.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.97, with an EV/FCF ratio of 429.42.
| EV / Earnings | 63.48 |
| EV / Sales | 11.62 |
| EV / EBITDA | 42.97 |
| EV / EBIT | 50.69 |
| EV / FCF | 429.42 |
Financial Position
The company has a current ratio of 2.34, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.34 |
| Quick Ratio | 1.20 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 2.65 |
| Interest Coverage | 42.92 |
Financial Efficiency
Return on equity (ROE) is 22.13% and return on invested capital (ROIC) is 15.99%.
| Return on Equity (ROE) | 22.13% |
| Return on Assets (ROA) | 12.13% |
| Return on Capital (ROIC) | 15.99% |
| Revenue Per Employee | 9.30M |
| Profits Per Employee | 1.70M |
| Employee Count | 1,643 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +166.81% in the last 52 weeks. The beta is 0.99, so Neuland Laboratories's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +166.81% |
| 50-Day Moving Average | 15,077.33 |
| 200-Day Moving Average | 10,239.07 |
| Relative Strength Index (RSI) | 35.04 |
| Average Volume (20 Days) | 96,828 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuland Laboratories had revenue of INR 15.28 billion and earned 2.80 billion in profits. Earnings per share was 217.98.
| Revenue | 15.28B |
| Gross Profit | 7.97B |
| Operating Income | 3.50B |
| Pretax Income | 3.76B |
| Net Income | 2.80B |
| EBITDA | 4.10B |
| EBIT | 3.50B |
| Earnings Per Share (EPS) | 217.98 |
Balance Sheet
The company has 1.90 billion in cash and 1.09 billion in debt, giving a net cash position of 808.72 million.
| Cash & Cash Equivalents | 1.90B |
| Total Debt | 1.09B |
| Net Cash | 808.72M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 13.95B |
| Book Value Per Share | 1,087.53 |
| Working Capital | 5.53B |
Cash Flow
In the last 12 months, operating cash flow was 2.46 billion and capital expenditures -2.04 billion, giving a free cash flow of 413.44 million.
| Operating Cash Flow | 2.46B |
| Capital Expenditures | -2.04B |
| Free Cash Flow | 413.44M |
| FCF Per Share | n/a |
Margins
Gross margin is 52.14%, with operating and profit margins of 22.92% and 18.30%.
| Gross Margin | 52.14% |
| Operating Margin | 22.92% |
| Pretax Margin | 24.60% |
| Profit Margin | 18.30% |
| EBITDA Margin | 26.82% |
| EBIT Margin | 22.92% |
| FCF Margin | 2.71% |
Dividends & Yields
Neuland Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 6.42% |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | 1.57% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |